Discovery and Optimization of Novel Sa FabI Inhibitors as Specific Therapeutic Agents for MRSA Infection
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Laiying Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Discovery, Methicillin-Resistant Staphylococcus aureus, Microbial Sensitivity Tests. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China, Cadre Health Research Project of Sichuan Ganyan.
Abstract (Originalsprache)
As the rate-limiting enzyme in fatty acid biosynthesis, Staphylococcus aureus enoyl-acyl carrier protein reductase (SaFabI) emerges as a compelling target for combating methicillin-resistant S. aureus (MRSA) infections. Herein, compound 1, featuring a 4-(1H-benzo[d]imidazol-2-yl)pyrrolidin-2-one scaffold, was identified as a potent SaFabI inhibitor (IC50 = 976.8 nM) from an in-house library. Subsequent optimization yielded compound n31, with improved inhibitory efficacy on enzymatic activity (IC50 = 174.2 nM) and selective potency against S. aureus (MIC = 1-2 μg/mL). Mechanistically, n31 directly inhibited SaFabI in cellular contexts. Moreover, n31 exhibited favorable safety and pharmacokinetic profiles, and dose-dependently treated MRSA-induced skin infections, outperforming the approved drug, linezolid. The chiral separation of n31 resulted in (S)-n31, with superior activities (IC50 = 94.0 nM, MIC = 0.25-1 μg/mL) and in vivo therapeutic efficacy. In brief, our research proposes (S)-n31 as a promising candidate for SaFabI-targeted therapy, offering specific anti-S. aureus efficacy and potential for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
- Editorial Office of Chinese Journal of Medical Genetics, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chen…
- Institute of traditional Chinese medicine, Sichuan College of Traditional Chinese Medicine, The Second Hospital of Traditional Chinese Medicine in Sichuan Province, Chengdu 610041, China.
- Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu 610041, China.
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
Förderung
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
- Cadre Health Research Project of Sichuan Ganyan
Zitieren
APA
Zhang, L., Yang, J., Xu, X., Zhang, J., Qiu, Z., Ju, Y., Luo, B., Liu, Y., Gou, X., Sui, J., Chen, B., Wang, Y., Tao, T., He, L., Yang, T., & Luo, Y. (2024). Discovery and Optimization of Novel Sa FabI Inhibitors as Specific Therapeutic Agents for MRSA Infection. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00320
Vancouver
Zhang L, Yang J, Xu X, Zhang J, Qiu Z, Ju Y, et al. Discovery and Optimization of Novel Sa FabI Inhibitors as Specific Therapeutic Agents for MRSA Infection. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00320
BibTeX
@article{Zhang2024,
author = {Zhang, Laiying and Yang, Jiaxing and Xu, Xin and Zhang, Jiangnan and Qiu, Zhiqiang and Ju, Yuan and Luo, Baozhu and Liu, Yan and Gou, Xupeng and Sui, Jing and Chen, Baoyi and Wang, Yanmei and Tao, Tao and He, Lei and Yang, Tao and Luo, Youfu},
title = {Discovery and Optimization of Novel Sa FabI Inhibitors as Specific Therapeutic Agents for MRSA Infection},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00320}
}
EUVIMED